Download PDF

1. Company Snapshot

1.a. Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.


Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Show Full description

1.b. Last Insights on PODD

Breaking News: Insulet Corporation reported its fourth quarter and full year 2025 results on February 18, 2026. The company posted quarterly earnings of $1.55 per share, surpassing the estimated $1.48 per share. This marks an increase from $1.15 per share in the same quarter last year. The strong demand for its wearable insulin pumps, which eliminate the need for daily injections, drove the better-than-expected results. Insulet's revenue also exceeded estimates. Our recommendation is to buy.

1.c. Company Highlights

2. Insulet Corporation Delivers Strong Q4 and Full-Year 2025 Results

Insulet Corporation reported a robust fourth quarter and full-year 2025 results, with total company revenues reaching $784 million, a 29% constant currency growth. The strong performance enabled the company to surpass $2.7 billion in revenue for the full year, more than doubling its revenue base over the last three years. The company's gross margin expanded 180 basis points to 73.6%, and operating margin expanded 270 basis points to 17.5%. Earnings per share (EPS) for the year was $1.44, slightly below estimates of $1.48.

Publication Date: Feb -19

📋 Highlights
  • Revenue Surge: Q4 revenue reached $784M (+29% YoY constant currency), with FY2025 total revenue exceeding $2.7B (+30% YoY constant currency).
  • Margin Expansion: Gross margin expanded 180 bps to 73.6%, and operating margin grew 270 bps to 17.6% in FY2025.
  • New Customer Growth: Record global new customer starts in FY2025, with 85% in the U.S. transitioning from multiple daily injections.
  • International Acceleration: International revenue surged 41.7% constant currency in Q4, driven by volume and pricing, with a $10B+ untapped type 1 market globally.
  • 2026 Guidance: Projects 21-23% Omnipod revenue growth and 20-22% total revenue growth, with adjusted EPS rising >25% and free cash flow stability.

Revenue Growth Drivers

The company's revenue growth was driven by strong demand for Omnipod 5 across type 1 and type 2 customers, with U.S. Omnipod revenue growing 28% in the fourth quarter and 27.2% for the year. International Omnipod revenue grew 50.7% on a reported basis and 41.7% on a constant currency basis for the fourth quarter. According to Ashley McEvoy, "We achieved record new customer starts across both the U.S. and international in the fourth quarter and for the full year, with the vast majority coming from people transitioning from multiple daily injections."

Guidance and Outlook

The company provided guidance for 2026, expecting Omnipod revenue to grow 21% to 23% and total company revenue to grow 20% to 22%. Adjusted EPS is expected to increase by more than 25%. The guidance reflects a balanced view of the outlook, and the company is confident in its ability to deliver the guidance. Analysts estimate next year's revenue growth at 19.0%, indicating a slight conservatism in the company's guidance.

Valuation Metrics

To understand what's priced in, we can look at Insulet Corporation's valuation metrics. The company's Price-to-Sales (P/S) Ratio is 6.7, and the EV/EBITDA ratio is 38.28. The ROE is 17.36%, indicating a strong return on equity. The Net Debt/EBITDA ratio is -1.53, indicating a net cash position. These metrics suggest that the company's strong growth prospects are reflected in its valuation.

3. NewsRoom

Card image cap

Financial Comparison: GE HealthCare Technologies (NASDAQ:GEHC) and Insulet (NASDAQ:PODD)

Feb -20

Source: defenseworld.net

Card image cap

Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations

Feb -19

Source: seekingalpha.com

Card image cap

PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Feb -19

Source: zacks.com

Card image cap

Insulet (NASDAQ:PODD) Shares Gap Up on Earnings Beat

Feb -19

Source: defenseworld.net

Card image cap

Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript

Feb -18

Source: seekingalpha.com

Card image cap

Insulet Corp (PODD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations

Feb -18

Source: gurufocus.com

Card image cap

Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars

Feb -18

Source: benzinga.com

Card image cap

Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Feb -18

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.72%)

6. Segments

United States Omnipod

Expected Growth: 13.5%

Insulet's Omnipod growth is driven by increasing adoption of tubeless insulin delivery systems, expanding reimbursement coverage, and growing awareness of the benefits of continuous glucose monitoring. Additionally, the company's strategic partnerships, investments in digital health technologies, and geographic expansion into new markets are contributing to the 13.5% growth rate.

International Omnipod

Expected Growth: 14.5%

Insulet's International Omnipod growth is driven by increasing adoption of tubeless insulin delivery systems, expanding global presence, and growing demand for diabetes management solutions. Strong marketing efforts, strategic partnerships, and favorable reimbursement trends also contribute to the 14.5% growth rate.

Drug Delivery

Expected Growth: 12.5%

Insulet Corporation's 12.5% growth in Drug Delivery is driven by increasing adoption of Omnipod insulin management systems, expansion into new markets, and growing demand for tubeless and wireless insulin delivery solutions. Additionally, strategic partnerships and investments in research and development are contributing to the company's growth momentum.

7. Detailed Products

Omnipod Insulin Management System

A wearable, tubeless insulin pump that provides continuous insulin delivery and insulin bolus dosing for people with diabetes.

Omnipod DASH System

A next-generation insulin management system that combines a wearable insulin pump with a mobile app and a Contour Next Link 2.4 meter.

Omnipod 5 System

An automated insulin delivery system that integrates with a continuous glucose monitor and a mobile app to provide personalized insulin dosing recommendations.

8. Insulet Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Insulet Corporation's Omnipod System is a unique product with limited substitutes, but patients may opt for traditional insulin pumps or multiple daily injections as alternatives.

Bargaining Power Of Customers

Insulet Corporation's customers, primarily patients with diabetes, have limited bargaining power due to the unique nature of the Omnipod System and the company's strong brand reputation.

Bargaining Power Of Suppliers

Insulet Corporation has a diversified supplier base, reducing dependence on individual suppliers and limiting their bargaining power.

Threat Of New Entrants

The medical device industry, particularly the insulin pump market, has high barriers to entry, including regulatory hurdles and significant R&D investments, making it challenging for new entrants to compete with Insulet Corporation.

Intensity Of Rivalry

The insulin pump market is moderately competitive, with a few established players, including Medtronic and Tandem Diabetes Care, but Insulet Corporation's unique product offerings and strong brand reputation help to differentiate it from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 65.95%
Debt Cost 3.95%
Equity Weight 34.05%
Equity Cost 8.88%
WACC 5.63%
Leverage 193.71%

11. Quality Control: Insulet Corporation passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Insulet

A-Score: 5.3/10

Value: 0.2

Growth: 9.6

Quality: 7.9

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
CONMED

A-Score: 4.8/10

Value: 7.4

Growth: 6.4

Quality: 5.9

Yield: 3.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Inari Medical

A-Score: 4.8/10

Value: 4.0

Growth: 8.0

Quality: 4.8

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
iRhythm Technologies

A-Score: 4.7/10

Value: 4.2

Growth: 6.1

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Bio-Rad

A-Score: 4.0/10

Value: 6.5

Growth: 2.3

Quality: 4.7

Yield: 0.0

Momentum: 5.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Integra LifeSciences

A-Score: 3.0/10

Value: 8.3

Growth: 2.3

Quality: 4.1

Yield: 0.0

Momentum: 0.5

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

241.89$

Current Price

241.89$

Potential

-0.00%

Expected Cash-Flows